Jake Murawski, PharmD, RPh

• Worked with Global Labeling Leads to edit pembrolizumab PI for approval by Swissmedic, National Medical Products Administration (NMPA), and South African Health Products Regulatory Authority (SAHPRA) • Participated in global labeling strategy meetings, evaluating regulatory variations in labeling requirements and their implications on product usage across targeted international markets

• Revised frequently asked questions, medical content letters, and Health Care Provider important safety information following Kerendia® label update • Co-led the creation of an interactive medical content letter to be utilized for adverse event inquiries • Formulated and distributed sales/MSL training on changes to the professional inquiry request form to notify field teams prior to launch • Refined call center phone tree and chatbot dialogue to streamline medical inquiries

• Built a customer relationship management tool for the MOL team to preserve meeting appointments and heath care decision maker interactions • Prioritized and coordinated the MOL strategy toward approaching key external stakeholders following a competitor’s FDA Advisory Committee meeting • Developed and presented slide decks to multiple medical affairs matrix teams covering gaps in current trial evidence and new market entities to prepare for product launch